The majority of the blockbuster drugs on the market today are therapeutic antibodies. However, despite record R&D investment and a growing global market for therapeutic antibodies, the ability for drug makers to obtain patent protection covering antibodies or treatment methods using antibodies has become a challenge.
Join Morrison Foerster’s Life Sciences group on September 13th for a discussion of the current state of antibody patent case law in the United States, including recent decisions regarding enablement and written description standards for claiming antibodies and unique patent considerations for innovators. We will also hear lessons learned from the team that recently helped Chugai Pharmaceuticals secure a $775 million patent litigation settlement involving method claims for an antibody product.
Discussion topics will include:
Eric Acker, Partner
Brian Kramer, Partner
Meghan Poon, Associate